Talk:Ipratropium bromide/salbutamol
This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||
|
Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Ipratropium bromide/salbutamol.
|
Patent expiration?
editDoes anyone know whe the Patent expires, or how to find this information? —Preceding unsigned comment added by 204.77.52.227 (talk) 13:57, 28 January 2009 (UTC)
In general, U.S. patent expriation can be easily found in the US FDA Orange book: http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm
Specifically, the patent for Combivent expires 09 Jun 2015. —Preceding unsigned comment added by 192.28.0.17 (talk) 21:17, 26 July 2010 (UTC)
"Confusing" tag response
editI've moved the following (that seems like a response to the tag posted in 2009) here as that is what talk pages are for. Raykyogrou0 (Talk) 12:24, 11 January 2014 (UTC)
In response to the "confusing section", here are links to the controversy in question if someone more knowledgeable in this area would be so kind as to consolidate it and wrap it up, so to speak:
· Medicare Reimbursement of Physician-Administered Drugs[1]
· Food & Drug Law Journal, 2009: Opacity and Cost Effectiveness Analysis in Medicare Coverate Decisions: Health Policy Encounters Administrative Law[2]
· The Comparative Effectiveness Research Landscape in the United States and Its Relevance to the Medicare Program[3]
Although [perhaps] unrelated, here is a recent FDA Safety Sheet for DuoNeb:.[4]
References
- ^ Medicare Reimbursement of Physician-Administered Drugs, House Hearing, 109th Congress, Serial No. 109-83
- ^ Opacity and Cost Effectiveness Analysis in Medicare Coverate Decisions, 64 Food & Drug L.J. 515
- ^ CMTP report for The Medicare Payment Advisory Commission, 31 May 2010
- ^ FDA Safety Sheet for DuoNeb